ClinicalTrials.gg
CompletedNCT01277601Updated Aug 26, 2016Results posted

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

A Phase 4 interventional study of TDF and Peg-IFN in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 171 sites in 19 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-08-26.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
751
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
2nd of 50
751 · median 117
Started
2011
with 5 others
Phase 4
22 of 50
none open now
Registered
17th of 50
by date
Lead sponsor
8 of 50
Gilead Sciences

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 2nd largest by enrollment, is one of 6 that started in 2011, is one of 22 in phase 4, and was the 17th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) plus peginterferon α-2a (Peg-IFN) combination therapy for 48 weeks versus standard of care TDF monotherapy or Peg-IFN monotherapy for 48 weeks in non-cirrhotic adults with chronic hepatitis B virus (HBV) as determined by loss of hepatitis B surface antigen (HBsAg).

The study will consist of 2 phases for participants in the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups. Following an initial 48 weeks of treatment, participants in these groups will be monitored for 24 weeks for signs of worsening HBV, and those meeting TDF retreatment and flare management criteria will be eligible to receive TDF monotherapy during a retreatment phase, up to Week 120.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • Chronic Hepatitis B
  • Hep B
  • Non cirrhotic
  • Tenofovir disoproxil fumarate (TDF)
  • Peginterferon α-2a (Peg-IFN)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age 18-75) with chronic (positive for serum hepatitis B surface antigen (HBsAg) or HBV DNA for at least 6 months) prior to baseline
  • Anti-HBV treatment-naive adults; adults who have taken oral anti-HBV nucleoside therapy with the last dose ≥ 24 weeks prior to screening are also eligible.
  • Positive or negative for hepatitis B e antigen (HBeAg)
  • HBV DNA ≥ 20,000 IU/ml (HBeAg-positive participants) and ≥ 2,000 IU/ml (HBeAg-negative participants)
  • (ALT) > 54 U/L and ≤ 400 U/L for men and > 36 U/L and ≤ 300 U/L for women
  • ≥ 70 mL/min
  • Negative serum pregnancy test for females of
  • Sexually active females of childbearing potential must agree to use a protocol-recommended method of throughout the study and for 30 days following the last dose of study medication
  • Lactating females must agree to discontinue nursing before initiation of study medicinal product

Exclusion criteria

Exclusion Criteria:

  • Known bridging fibrosis or cirrhosis and/or decompensated liver disease
  • Evidence of hepatocellular carcinoma
  • Significant kidney, heart, lung, neurological, disease, or bone disease (eg, osteomalacia,chronic osteomyelitis, osteogenesis imperfecta, osteochondrosis, multiple bone fractures)
  • \< 1,500/mm\^3, \< 100,000/mm\^3, \< 10 g/dL (female) or \< 11 g/dL (male)
  • History of severe depression or severe psychiatric disease
  • Thyroid dysfunction
  • Coinfection with , virus (HCV) or hepatitis D virus (HDV)
  • Pregnant
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
751 participants (actual)

Study arms

  • Experimental
    TDF+Peg-IFN 48 Weeks

    TDF plus Peg-IFN for 48 weeks

    Drug: TDF · Drug: Peg-IFN

  • Experimental
    TDF 48 Weeks + Peg-IFN 16 Weeks

    TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks

    Drug: TDF · Drug: Peg-IFN

  • Active comparator
    TDF 120 Weeks

    TDF monotherapy for 120 weeks

    Drug: TDF

  • Active comparator
    Peg-IFN 48 Weeks

    Peg-IFN monotherapy for 48 weeks

    Drug: Peg-IFN

Interventions

  • DrugTDF

    TDF 300 mg tablets administered orally once daily

    Also known as: Viread®

  • Peg-IFN 180 µg administered via subcutaneous injection once weekly

    Also known as: Pegasys®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone

    Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.

    Time frame: Baseline; Week 72

Secondary outcomes

  1. Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus Peg-IFN (16 Weeks) Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone

    Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.

    Time frame: Baseline; Week 72

  2. Percentage of Participants With HBsAg Loss at Weeks 96 and 120

    Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 96 comprised study Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised study Week 114 through Week 126, so results up to Week 126 are included in this analysis.

    Time frame: Baseline; Weeks 96 and 120

  3. Percentage of Participants With HBsAg Seroconversion at Weeks 72, 96, and 120

    HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis. The analysis visit window for Week 96 comprised Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised Week 114 through Week 120.

    Time frame: Baseline; Weeks 72, 96, and 120

  4. Percentage of Participants With HBeAg Loss and Seroconversion at Week 72

    Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.

    Time frame: Baseline; Week 72

  5. Percentage of Participants With HBeAg Loss and Seroconversion at Week 96

    Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.

    Time frame: Baseline; Week 96

  6. Percentage of Participants With HBeAg Loss and Seroconversion at Week 120

    Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.

    Time frame: Baseline; Week 120

  7. Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 72

    For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.

    Time frame: Week 72

  8. Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 96

    For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.

    Time frame: Week 96

  9. Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 120

    For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.

    Time frame: Week 120

  10. Percentage of Participants With Normal ALT at Week 72

    Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.

    Time frame: Week 72

  11. Percentage of Participants With Normal ALT at Week 96

    Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.

    Time frame: Week 96

  12. Percentage of Participants With Normal ALT at Week 120

    Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.

    Time frame: Week 120

  13. Percentage of Participants Who Required Retreatment

    Participants in the TDF 120 week group were not eligible to enter the retreatment phase and are not presented.

    Time frame: Up to 120 weeks

07

Results

Posted Sep 9, 2015

Participant flow

Participants were enrolled at study sites in North America, Europe, Asia, and Australia. The first participant was screened on 12 April 2011. The last study visit occurred on 17 July 2015.

Participant flow — Overall Study
MilestoneTDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeeksTDF 120 WeeksPeg-IFN 48 Weeks
Started188187190186
Completed151139163150
Not completed37482736
Withdrew: Adverse event5307
Withdrew: Withdrawal by subject1821817
Withdrew: Lost to follow-up7942
Withdrew: Physician decision3516
Withdrew: Pregnancy2241
Withdrew: Noncompliance with study drug1320
Withdrew: Subject never dosed with study drug1231
Withdrew: Protocol violation0250
Withdrew: Subject terminated from study by sponsor0102

Outcome measures

PrimaryPercentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone

Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.

Time frame:
Baseline; Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone
percentage of participantsTDF+Peg-IFN 48 WeeksTDF 120 WeeksPeg-IFN 48 Weeks
Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus Peg-IFN Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone9.050.002.84
Statistical analysis
  • TDF+Peg-IFN 48 Weeks vs TDF 120 Weeks · Log Rank · p = < 0.001 (Raw p-values comparing treatments were based on a log-rank test stratified by HBeAg status and viral genotype.)
  • TDF+Peg-IFN 48 Weeks vs Peg-IFN 48 Weeks · Log Rank · p = 0.002 (Raw p-values comparing treatments were based on a log-rank test stratified by HBeAg status and viral genotype.)
SecondaryPercentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus Peg-IFN (16 Weeks) Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone

Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis.

Time frame:
Baseline; Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus Peg-IFN (16 Weeks) Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone
percentage of participantsTDF 48 Weeks + Peg-IFN 16 WeeksTDF 120 WeeksPeg-IFN 48 Weeks
Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus Peg-IFN (16 Weeks) Combination Versus Peg-IFN Alone for 48 Weeks or TDF Alone2.830.002.84
SecondaryPercentage of Participants With HBsAg Loss at Weeks 96 and 120

Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 96 comprised study Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised study Week 114 through Week 126, so results up to Week 126 are included in this analysis.

Time frame:
Baseline; Weeks 96 and 120
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Loss at Weeks 96 and 120
percentage of participantsTDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeeksTDF 120 WeekPeg-IFN 48 Weeks
Week 969.693.490.002.84
Week 12010.363.490.003.51
SecondaryPercentage of Participants With HBsAg Seroconversion at Weeks 72, 96, and 120

HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive. Proportions are based on a Kaplan-Meier estimate. The analysis visit window for Week 72 comprised Week 70 through Week 78, so results up to Week 78 are included in this analysis. The analysis visit window for Week 96 comprised Week 90 through Week 102, so results up to Week 102 are included in this analysis. The analysis visit window for Week 120 comprised Week 114 through Week 120.

Time frame:
Baseline; Weeks 72, 96, and 120
Reported as:
Number · percentage of participants
Percentage of Participants With HBsAg Seroconversion at Weeks 72, 96, and 120
percentage of participantsTDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeeksTDF 120 WeeksPeg-IFN 48 Weeks
Week 728.050.560.002.87
Week 968.050.560.002.87
Week 12010.080.560.002.87
SecondaryPercentage of Participants With HBeAg Loss and Seroconversion at Week 72

Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.

Time frame:
Baseline; Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss and Seroconversion at Week 72
percentage of participantsTDF+Peg-IFN 48 Week (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Weeks + Peg-IFN 16 Week (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Weeks (Not Retreated)Peg-IFN 48 Weeks (Retreated)
HBeAg Loss35.515.632.815.914.732.814.3
HBeAg Seroconversion28.915.631.113.612.831.314.3
SecondaryPercentage of Participants With HBeAg Loss and Seroconversion at Week 96

Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.

Time frame:
Baseline; Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss and Seroconversion at Week 96
percentage of participantsTDF+Peg-IFN 48 Week (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Weeks + Peg-IFN 16 Week (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Weeks (Not Retreated)Peg-IFN 48 Weeks (Retreated)
HBeAg Loss43.220.345.514.818.337.814.5
HBeAg Seroconversion36.418.843.213.116.529.713.0
SecondaryPercentage of Participants With HBeAg Loss and Seroconversion at Week 120

Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive. Percentages were based on the number of subjects with non-missing HBeAg results or missing HBeAg results imputed as failures at each visit. For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.

Time frame:
Baseline; Week 120
Reported as:
Number · percentage of participants
Percentage of Participants With HBeAg Loss and Seroconversion at Week 120
percentage of participantsTDF+Peg-IFN 48 Week (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Weeks + Peg-IFN 16 Week (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Weeks (Not Retreated)Peg-IFN 48 Weeks (Retreated)
HBeAg Loss38.625.037.523.120.233.318.6
HBeAg Seroconversion29.521.935.015.415.625.017.1
SecondaryPercentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 72

For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 72
percentage of participantsTDF+Peg-IFN 48 Weeks (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Weeks (Not Retreated)Peg-IFN 48 Weeks (Retreated)
Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 7215.326.214.515.184.911.740.4
SecondaryPercentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 96

For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 96
percentage of participantsTDF+Peg-IFN 48 Weeks (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Weeks (Not Retreated)Peg-IFN 48 Weeks (Retreated)
Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 9621.768.015.780.283.813.970.8
SecondaryPercentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 120

For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.

Time frame:
Week 120
Reported as:
Number · percentage of participants
Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 120
percentage of participantsTDF+Peg-IFN 48 Weeks (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Weeks (Not Retreated)Peg-IFN 48 Weeks (Retreated)
Percentage of Participants With Virological Response (HBV DNA < 117 IU/mL) at Week 12032.481.318.883.582.213.282.1
SecondaryPercentage of Participants With Normal ALT at Week 72

Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 72, and in the "Retreated" column for participants who did enter the retreatment phase by Week 72.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 72
percentage of participantsTDF+Peg-IFN 48 Weeks (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Week (Not Retreated)Peg-IFN 48 Weeks (Retreated)
AASLD Criteria42.118.340.718.247.635.09.2
Central Laboratory Criteria59.540.057.634.872.457.533.8
SecondaryPercentage of Participants With Normal ALT at Week 96

Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 96, and in the "Retreated" column for participants who did enter the retreatment phase by Week 96.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 96
percentage of participantsTDF+Peg-IFN 48 Weeks (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Week (Not Retreated)Peg-IFN 48 Weeks (Retreated)
AASLD Criteria43.242.934.146.148.134.739.8
Central Laboratory Criteria55.671.452.473.573.047.268.1
SecondaryPercentage of Participants With Normal ALT at Week 120

Normal ALT was ≤ 30 U/L for males and ≤ 19 U/L for females (based on the American Association for the Study of Liver Diseases (AASLD) 2008 guidelines), and ≤ 41 U/L for males and ≤ 31 U/L for females (based on central laboratory upper limit of the normal range (ULN) for ALT). For the TDF+Peg-IFN 48 Weeks, TDF 48 Weeks + Peg-IFN 16 Weeks, and Peg-IFN 48 Weeks groups, data are presented in the "Not Retreated" column for participants who had not entered the retreatment phase by Week 120, and in the "Retreated" column for participants who did enter the retreatment phase by Week 120.

Time frame:
Week 120
Reported as:
Number · percentage of participants
Percentage of Participants With Normal ALT at Week 120
percentage of participantsTDF+Peg-IFN 48 Weeks (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Week (Not Retreated)Peg-IFN 48 Weeks (Retreated)
AASLD Criteria39.254.530.448.748.630.947.0
Central Laboratory Criteria44.672.340.678.373.041.273.5
SecondaryPercentage of Participants Who Required Retreatment

Participants in the TDF 120 week group were not eligible to enter the retreatment phase and are not presented.

Time frame:
Up to 120 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Retreatment
percentage of participantsTDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeeksPeg-IFN 48 Weeks
Percentage of Participants Who Required Retreatment60.262.563.2

Adverse events

Collected over Up to 120 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TDF+Peg-IFN 48 Weeks (Not Retreated)—21/186 (11.3%)147/186 (79%)
TDF+Peg-IFN 48 Weeks (Retreated)—7/112 (6.3%)26/112 (23.2%)
TDF 48 Week + Peg-IFN 16 Weeks (Not Retreated)—18/184 (9.8%)142/184 (77.2%)
TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)—3/115 (2.6%)31/115 (27%)
TDF 120 Weeks—13/185 (7%)89/185 (48.1%)
Peg-IFN 48 Weeks (Not Retreated)—18/185 (9.7%)152/185 (82.2%)
Peg-IFN 48 Weeks (Retreated)—6/117 (5.1%)33/117 (28.2%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventTDF+Peg-IFN 48 Weeks (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Week + Peg-IFN 16 Weeks (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Weeks (Not Retreated)Peg-IFN 48 Weeks (Retreated)
Alanine aminotransferase increasedInvestigations6/1863/1128/1842/1151/1857/1852/117
HepatitisHepatobiliary disorders3/1862/1124/1840/1151/1857/1851/117
Aspartate aminotransferase increasedInvestigations1/1862/1121/1840/1150/1852/1851/117
Cholecystitis chronicHepatobiliary disorders0/1860/1120/1840/1152/1850/1850/117
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/1861/1120/1840/1150/1850/1850/117
CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1861/1120/1840/1150/1850/1850/117
Mixed hepatocellular cholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1861/1120/1840/1150/1850/1850/117
Hepatic encephalopathyNervous system disorders0/1860/1120/1841/1150/1850/1850/117
Amylase increasedInvestigations0/1860/1120/1840/1150/1850/1851/117
Lipase increasedInvestigations0/1860/1120/1840/1150/1850/1851/117
Most frequent other events
Showing 10 of 30
Most frequent other events
EventTDF+Peg-IFN 48 Weeks (Not Retreated)TDF+Peg-IFN 48 Weeks (Retreated)TDF 48 Week + Peg-IFN 16 Weeks (Not Retreated)TDF 48 Weeks + Peg-IFN 16 Weeks (Retreated)TDF 120 WeeksPeg-IFN 48 Weeks (Not Retreated)Peg-IFN 48 Weeks (Retreated)
HeadacheNervous system disorders54/1863/11237/1843/11516/18552/1854/117
AlopeciaSkin and subcutaneous tissue disorders46/1860/11232/1841/1152/18545/1851/117
PyrexiaGeneral disorders39/1861/11236/1841/1158/18543/1852/117
FatigueGeneral disorders40/1862/11233/1844/11521/18541/1856/117
Decreased appetiteMetabolism and nutrition disorders23/1860/11236/1842/1152/18518/1850/117
MyalgiaMusculoskeletal and connective tissue disorders29/1860/11236/1841/1152/18535/1851/117
NauseaGastrointestinal disorders26/1860/11224/1843/11511/18513/1856/117
PruritusSkin and subcutaneous tissue disorders14/1860/11214/1842/1154/18521/1850/117
NasopharyngitisInfections and infestations5/1863/11216/1843/11520/1856/1853/117
AstheniaGeneral disorders20/1860/1129/1841/1154/18512/1851/117

Baseline characteristics

Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug. Participants were analyzed by actual treatment received. 11 participants were never dosed are not included in the Safety Analysis Set due to the following reasons for discontinuation: 7 = Subject Never Dosed with Study Drug; 4 = Withdrawal by Subject.

Age, Continuous
Age, Continuous(years)TDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeekTDF 120 WeeksPeg-IFN 48 WeeksTotal
Mean38 ± 10.737 ± 9.936 ± 10.838 ± 10.537 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)TDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeekTDF 120 WeeksPeg-IFN 48 WeeksTotal
Female59656466254
Male127119121119486
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeekTDF 120 WeeksPeg-IFN 48 WeeksTotal
Hispanic or Latino443718
Not Hispanic or Latino182179181177719
Unknown or Not Reported01113
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)TDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeekTDF 120 WeeksPeg-IFN 48 WeeksTotal
Asian142134141137554
Black or African American534618
Native Hawaiian or Other Pacific Islander20013
White36453941161
Other12104
Region of Enrollment
Region of Enrollment(participants)TDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeekTDF 120 WeeksPeg-IFN 48 WeeksTotal
Romania121513949
Singapore757827
Hong Kong2524272197
United States1917232685
United Kingdom231410
Portugal03003
India1059630
Spain333514
Greece03249
Canada1914141158
Netherlands21014
Turkey566724
Taiwan2015121966
Korea, Republic of34383835145
Poland476522
Italy214411
Australia1014151453
France631313
Germany674320
Hepatitis B Surface Antigen (HBsAg)
Hepatitis B Surface Antigen (HBsAg)(log 10 IU/mL)TDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeekTDF 120 WeeksPeg-IFN 48 WeeksTotal
Mean3.88 ± 0.8403.84 ± 0.8493.89 ± 0.8123.76 ± 0.8443.84 ± 0.836
Hepatitis B e Antigen (HBeAg) Status
Hepatitis B e Antigen (HBeAg) Status(participants)TDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeekTDF 120 WeeksPeg-IFN 48 WeeksTotal
Reactive108105109106428
Nonreactive78797679312
Hepatitis B Virus (HBV) DNA
Hepatitis B Virus (HBV) DNA(log 10 IU/mL)TDF+Peg-IFN 48 WeeksTDF 48 Weeks + Peg-IFN 16 WeekTDF 120 WeeksPeg-IFN 48 WeeksTotal
Mean7.06 ± 1.5427.13 ± 1.5057.02 ± 1.5506.94 ± 1.6197.04 ± 1.553

2 further baseline measures are reported on the registry.

08

Study locations

171 sites
  • Asian Pacific Liver Center
    Los Angeles, California, United States
  • Stanford University Medical Center
    Palo Alto, California, United States
  • Research and Education Inc
    San Diego, California, United States
  • San Jose Gastroenterology
    San Jose, California, United States
  • Avail Clinical Research, LLC
    Deland, Florida, United States
  • Centre for Advanced Gastroenterology
    Maitland, Florida, United States
  • University of Miami / Jackson Memorial Medical Center
    Miami, Florida, United States
  • University of Chicago
    Chicago, Illinois, United States
  • LSU Gastroenterology/Center for Digestive Diseases
    New Orleans, Louisiana, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana, United States
  • Digestive Disease Associates
    Baltimore, Maryland, United States
  • Tufts Medical Center
    Boston, Massachusetts, United States
  • Henry Ford Hospital
    Detroit, Michigan, United States
  • ID Care, Inc.
    Hillsborough, New Jersey, United States
  • Medical Procare, PLLC
    Flushing, New York, United States
  • North Shore University Hospital
    Great Neck, New York, United States
  • Beth Israel Medical Center
    New York, New York, United States
  • New York Univ. Medical Center
    New York, New York, United States
  • Weill Cornell Medical College of Cornell University
    New York, New York, United States
  • Private Practice
    Philadelphia, Pennsylvania, United States
  • Advanced Liver Therapies at St. Luke's Episcopal Hospital
    Houston, Texas, United States
  • Kelsey Research Foundation
    Houston, Texas, United States
  • Liver Associates of Texas,
    Houston, Texas, United States
  • University of Utah
    Salt Lake City, Utah, United States
  • Liver Institute of Virginia, Bon Secours Health System
    Richmond, Virginia, United States
  • McGuire Research Institute
    Richmond, Virginia, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales, Australia
  • Concord Repatriation General Hospital
    Concord, New South Wales, Australia
  • Saint George's Hospital
    Kogarah, New South Wales, Australia
  • Liverpool Hospital,Gastroenterology Department
    Liverpool, New South Wales, Australia
  • Westmead Hospital
    Westmead, New South Wales, Australia
  • Royal Brisbane & Women's Hospital
    Herston, Queensland, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland, Australia
  • Royal Adelaide Hospital
    Adelaide SA, South Australia, Australia
  • Flinders Medical Center
    Adelaide, South Australia, Australia
  • Monash Medical Centre
    Clayton, Victoria, Australia
  • Saint Vincents Hospital
    Fitzroy, Victoria, Australia
  • Western Hospital
    Footscray, Victoria, Australia
  • Austin Health
    Heidelberg, Victoria, Australia
  • Alfred Hospital
    Melbourne, Victoria, Australia
  • Box Hill Hospital
    Melbourne, Victoria, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria, Australia
  • Fremantle Hospital
    Fremantle, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Australia
  • Royal Perth Hospital
    Perth, Australia
  • Heritage Med Research Clinic, Univ of Calgary
    Calgary, Alberta, Canada
  • University of Alberta, Zeidler Ledcore Centre
    Zeidler Ledcore Centre, Alberta, Canada
  • Gastrointestional Research Institute
    Vancouver, British Columbia, Canada
  • Gordon & Leslie Diamond Health Care Centre
    Vancouver, British Columbia, Canada
  • Liver and Intestinal Research Centre
    Vancouver, British Columbia, Canada
  • The Ottawa Hospital,Division of Infectious Diseases
    Ottawa, Ontario, Canada
  • Toronto General Hospital
    Toronto, Ontario, Canada
  • Toronto Liver Centre
    Toronto, Ontario, Canada
  • Hôpital Beaujon, Service Hepatologie- Centre Pierre Abrami
    Clichy, Cedex, France
  • Hôpital de la Croix Rousse
    Lyon, Cedex, France
  • Hopital Tenon
    Paris, France
  • Centre Hospitalier Universitaire de Rennes
    Rennes Cedex 9, France
  • Hopital Charles Nicolle
    Rouen, France
  • Centre Hospitalier Regional et Universitaire de Strasbourg, Hopital Civil
    Strasbourg, France
  • Centre Hospitalier Universitaire Purpan
    Toulouse, France
  • Hopital Paul Brousse
    Villejuif Cedex, France
  • Johannes Gutenberg-Universitat Mainz,
    Mainz, Rheinland-pfalz, Germany
  • Charite Berlin
    Berlin, Germany
  • Universitätsklinikum Essen - klinikum für Gastroenterolgie und Hepatologie,
    Essen, Germany
  • Johann-Wolfgang-Goethe Universitat,
    Frankfurt, Germany
  • Asklepios Westklinikum
    Hamburg, Germany
  • Medizinische Hochschule Hannover,Hastroenterologie und Hepatologie
    Hannover, Germany
  • Universitatsklinik Koln
    Köln, Germany
  • Universitatsklinikum Leipzig
    Leipzig, Germany
  • Ippokratio Hospital Salonica
    Thessaloniki, Attica, Greece
  • Ippokratio Hospital Athens
    Attica, Greece
  • General University Hospital of Patras
    Patra, Greece
  • Hippokration General Hospital of Thessaloniki
    Thessaloniki, Greece
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Princess Margaret Hospital
    Kowloon, Hong Kong
  • Prince of Wales Hospital
    Shatin, Hong Kong
  • Alice Ho Miu Ling Nethersole Hospital
    Tai Po, Hong Kong
  • Global Hospital, Lakdi Ka Pul
    Hyderabad, Andhra Pradesh, India
  • Institute of digestive and liver disease, Dispur Hospital Ganeshguri
    Guwahati, Assam, India
  • Vedanta Institute of Medical Sciences
    Ahmedabad, Gujarat, India
  • Liver Clinic
    Surat, Gujarat, India
  • Manipal Hospitals
    Bangalore, Karnataka, India
  • Department of Hepatology, Institute of Liver Diseases, HPB Surgery and Transplant, Global Hospital
    Mumbai, Maharashtra, India
  • Seth GS Medical College and KEM Hospital, Acharya Donde Marg,Parel
    Mumbai, Maharashtra, India
  • Midas Institute of Gastroenterology
    Nagpur, Maharashtra, India
  • Dharamasi Hospital,Chandni Chowk, South Shivajinagar,
    Sangli, Maharashtra, India
  • All India Institute of Medical Sciences, Ansari Nagar
    Delhi, New Delhi, India
  • VGM Hospital
    Coimbatore, Tamil Nadu, India
  • Institute of Post Graduate Medical Education And Research
    Kolkata, West Bengal, India
  • Institute of Liver and Biliary Sciences
    New Delhi, India
  • Azienda Ospedaliero-Universitaria di Cagliari
    Monserrato, Cagliari, Italy
  • Fondazione IRCCS Ca Granda - Ospedale Maggiore Policlinico
    Milano, Italy
  • Ospedale San Raffaele
    Milano, Italy
  • Seconda Universita degli Studi di Napoli
    Napoli, Italy
  • Azienda Ospedaliera di Parma,Department of Infectious Diseases and hepatology
    Parma, Italy
  • Fondazione PTV - Policlinico Tor Vergata
    Roma, Italy
  • Policlinico Umberto I
    Rome, Italy
  • University of Milan,Azienda Ospedaliera San Giovanni, Battista di Torino,Dipartimento di Gastroenterologia
    Torino, Italy
  • SoonChunHyang University Hospital Cheonan
    Cheonan, Chungcheon, Korea, Republic of
  • Yonsei Unversity Wonju College of Medicine Wonju Christian Hospital
    Wonju, Gangwon-do, Korea, Republic of

Showing the first 100 of 171 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, Petersen J, Foster GR, Lou L, Martins EB, Dinh P, Lin L, Corsa A, Charuworn P, Subramanian GM, Reiser H, Reesink HW, Fung S, Strasser SI, Trinh H, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HL; Study 149 Investigators. Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology. 2016 Jan;150(1):134-144.e10. doi: 10.1053/j.gastro.2015.09.043. Epub 2015 Oct 8. PubMed 26453773 ↗
  • Chan HL, Elkhashab M, Trinh H, Tak WY, Ma X, Chuang WL, Kim YJ, Martins EB, Lin L, Dinh P, Charuworn P, Foster GR, Marcellin P. Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. J Hepatol. 2015 Nov;63(5):1086-92. doi: 10.1016/j.jhep.2015.06.025. Epub 2015 Jul 2. PubMed 26143444 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Aug 2014 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2011
First posted
Jan 17, 2011
Start
Apr 2011
Primary completionActual
Aug 2014
CompletionActual
Jul 2015
Results first posted
Sep 9, 2015
Last update
Aug 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01277601
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jan 17, 2011
Start date
Apr 2011
Primary completion
Aug 2014
Completion
Jul 2015
Results posted
Sep 9, 2015
Last update
Aug 26, 2016

Study contacts

Belinda Jump
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tenofovir · Interferons

Start the discussion